KRAS and neoplasm: A more complete understanding of the frequency and nature of these events is important, as these models are routinely used in preclinical studies of novel therapeutic agents8,14,22, and a pervasive assumption is that the tumors are only driven by the Kras and Trp53 transgenes15 or that non-cell autonomous factors predominate in driving tumor progression4.